Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bleeding breakthrough fizzles: fibrinogen trial for chemo patients halted after just one patient

NCT ID NCT05091684

Terminated Disease control Sponsor: Centre Hospitalier Universitaire de Saint Etienne Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a single injection of fibrinogen concentrate followed by a platelet transfusion in blood cancer patients with severe bleeding who did not respond to standard platelet transfusions. The goal was to see if it improved blood clotting. However, the trial was terminated early after enrolling only one participant, so no meaningful conclusions can be drawn.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
fibrinogen concentrate
What this could lead to
If it worked, this could offer a way to manage severe bleeding in patients who don't respond to platelet transfusions.
What could go wrong
The trial was terminated early with only 1 participant, so there is very little data. It is unclear if the approach is safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLEEDING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematologic disorder hematopoietic and lymphoid system neoplasm Hemorrhage hemorrhagic disease thrombocytopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLEEDING HEMATOLOGICAL PATIENTS PLATELET REFRACTORINESS

Contacts and locations

Locations

  • CHU de Saint-Etienne

    Saint-Etienne, 42055, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.